ReviewJournal of inflammation research2025
Role of Ferroptosis in Alveolar Epithelial Cells in Acute Respiratory Distress Syndrome.
Review in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Serum lipidome remodeling in viral pneumonia: from pathophysiology to therapeutics.Frontiers in immunology · 2026Review
- Cell-specific exosomes in sepsis-associated ARDS: from immunometabolic reprogramming to precision medicine.Frontiers in immunology · 2026Review
- Exosomal miR-148a-3p from LPS-Activated Macrophages Promotes M1 Polarization and Ferroptosis-Related Characteristics of Recipient Macrophages by Reducing SLC7A11.Infection and drug resistance · 2026Article
- miR-21-5p attenuates hyperoxia-induced lung injury by modulating YAP1-dependent ferroptosis.Frontiers in pharmacology · 2026Article
- Ferroptosis-immune-metabolic axis in asthma: mechanistic crosstalk, endotype-specific regulation, and translational targeting.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute respiratory distress syndrome (ARDS) is a life-threatening condition characterized by the rapid onset of respiratory failure resulting from extensive inflammation and damage to the alveolar‒capillary barrier. ARDS can be triggered by various factors, including pneumonia, sepsis, trauma, and aspiration, emphasizing its relevance in the field of critical care medicine. Ferroptosis is a novel form of regulated cell death that plays a crucial role in the pathophysiology of ARDS. Unlike apoptosis and necrosis, ferroptosis is characterized by the lethal accumulation of lipid peroxides (LPOs), which is driven primarily by dysregulated iron metabolism and oxidative stress. Alveolar epithelial cells (AECs), pivotal in maintaining pulmonary homeostasis and gas exchange, exhibit heightened vulnerability to ferroptosis in ARDS. The inflammatory microenvironment associated with this syndrome further highlights the potential impact of ferroptosis on lung injury and repair processes. This review elucidates the multifaceted relationships among ferroptosis, inflammation, and oxidative stress in AECs, providing insights into the pathological mechanisms through which ferroptosis contributes to lung injury and the disruption of the alveolar‒capillary barrier. Furthermore, the therapeutic implications of targeting ferroptosis in ARDS management, including the roles of antioxidants and intracellular nutrients in mitigating oxidative damage and preserving lung function, are discussed. These mechanistic insights underscore ferroptosis as a tractable therapeutic node in ARDS pathobiology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.